This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

April 28, 2025

To whom it may concern:

Company	D.Western Therapeutics Institute, Inc.
Representative	Yuichi Hidaka, President and CEO
	(Code No. 4576)
Contact	Sayako Matsubara, Director
TEL	052-218-8785

Announcement of the commencement of joint research on next-generation drug development for the creation of new eye disease treatments

We are pleased to announce that we have entered into a joint research agreement with Professor Hitoshi Kasai of the Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, a National University Corporation, to develop next-generation formulations for the treatment of eye diseases. This joint research will be conducted through the Aoba Foundation For The Promotion of Engineering.

Our company is currently focusing on the field of ophthalmology. However, there are various types of eye diseases, and retinal diseases such as retinitis pigmentosa, diabetic retinopathy, and age-related macular degeneration are considered to have high unmet medical needs, as there are currently no adequate treatments available. Additionally, for conditions like cataracts, where surgery is the primary treatment option, there is a significant need for drug-based therapies. The number of patients suffering from these conditions is increasing annually, and we believe that developing next-generation formulation technologies is a critical research area for creating new treatments.

In this joint research, we will work with Professor Hitoshi Kasai, who specializes in organic nanomaterials and nanodrugs, to develop next-generation formulations suitable for the treatment of eye diseases. The new formulations will aim to enhance drug efficacy and improve intraocular penetration.

Our company is engaged in drug discovery activities to create new drug candidates. We will promote this joint research to further expand our pipeline and meet patients' needs.

Due to this matter, there will be no change to the earnings forecast for the fiscal year ending December 2025.

End